White blood cell count >= 4000 cells/mm^3Xx_NEWLINE_xXWhite blood cell count (WBC) >= 4,000/mlXx_NEWLINE_xXB-ALL patients must have an initial white blood cell count < 50,000/uLXx_NEWLINE_xXWhite blood cell (WBC) > 3.0Xx_NEWLINE_xXWhite blood cells (WBC) >= 3,000 cells/uL (3.0 x 10^9 L) orXx_NEWLINE_xXTotal white blood cells (WBC) >= 4.0 x 10^3/mcL within 28 days prior to registrationXx_NEWLINE_xXWhite blood cells (WBC) >= 3500/uLXx_NEWLINE_xXWhite blood count >= 3,000/uL, obtained within 4 weeks prior to randomizationXx_NEWLINE_xXWhite blood count >= 3,000/uLXx_NEWLINE_xXPatients with white blood cell (WBC) > 30,000 are not eligible to start therapy; however, it is permissible to use glucocorticoids and/or hydroxyurea to diminish peripheral WBC to less than 30,000 provided these agents are stopped at least 24 hours prior to the first dose of MLN0128 (TAK-228)Xx_NEWLINE_xXTotal absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells [WBC]) is at least 1000/uLXx_NEWLINE_xXWhite blood cell count (WBC) >= 2,000/mcL; must be obtained within 28 days prior to registrationXx_NEWLINE_xXWhite blood cell (WBC) >= 2000/uLXx_NEWLINE_xXWhite blood cells >= 2000/uL, within 4 weeks of randomizationXx_NEWLINE_xXWithin 28 days prior to administration of study treatment: White blood count (WBC) > 3 x 10^9/LXx_NEWLINE_xXWhite blood cell count (WBC) >= 3 x 10^9/LXx_NEWLINE_xX